GlobeNewsWire
18 Aug 2026, 00:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Capricor Therapeutics is facing a securities fraud class action lawsuit alleging misleading characterizations of trial endpoints and undisclosed modifications. — Allegations of data manipulation or fraud in clinical trials are highly material for biotech firms and typically trigger significant sell-offs.
-0.70Capricor management omitted the analyst Q&A session from its Q2 2026 earnings call, citing sensitive ongoing discussions with the FDA. — Lack of transparency and refusal to answer analyst questions during earnings calls is generally viewed by the market as a red flag for hidden bad news.
-0.50The company holds $237.9 million in cash and marketable securities. — A strong cash position provides a runway to sustain operations and fight legal battles despite current losses.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Capricor reported a net loss of $40.7 million for Q2 2026. — While losses are common for clinical-stage biotech, it confirms a continued burn of capital.
-0.20Which stocks this story touches
Company reported a $40.7 million net loss, omitted analyst Q&A from earnings, and faces a securities fraud class action lawsuit.
The company is facing a securities class action after its stock plunged due to allegedly misleading financial statements.
The company is facing a securities class action following a stock plunge due to an alleged massive over-hedge loss.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
